Syncom Formulations (India) Ltd

Ticker: SYNCOMF
Risky 48/100

☆ Add to Watchlist

Investing Reference

Price
16.44
Market Cap
1539.81
Debt/Equity
0.0134
ROE %
15.688
PB
4.5003
Promoter %
50.569
Pledge %
0.000
1Y Rev Growth %
74.220
5Y Rev Growth %
NP Margin %
10.248
NP Margin 5Y Avg %

Trading Reference

1M Return %
3.222
6M Return %
1.859
1Y Return %
-18.614
% Away 52W High
45.195
% Away 52W Low
16.596
Daily Volume
1298542
Investment Verdict
Hold
Score 69/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 25/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.

Summary

Syncom Formulations (India) Ltd shows potential in the pharmaceutical sector with steady growth.

✅ Positives
  • Strong revenue growth over the past year
  • Diverse product portfolio in generics
  • Expanding international market presence

⚠️ Negatives
  • High competition in the pharmaceutical industry
  • Regulatory challenges affecting operations
  • Volatility in raw material prices

Verdict
Moderate growth potential with risks.
Recommendation: Consider buying on dips.
Upside Probability: 25%   |   Downside Probability: 15%
Last generated: 31/10/2025

More Options

Business Overview

Syncom Formulations (India) Ltd is a prominent player in the pharmaceutical sector, specializing in the development and manufacturing of quality formulations. Catering to healthcare providers and patients, the company focuses on delivering affordable and effective medications. With a commitment to innovation and compliance with international standards, Syncom plays a crucial role in enhancing healthcare accessibility in India. Its robust product portfolio and strategic partnerships position it well for growth in a competitive market.

  • Established leader in pharmaceutical formulations
  • Focus on affordable healthcare solutions
  • Strong commitment to quality and compliance
  • Diverse product portfolio catering to various therapeutic areas
  • Strategic partnerships enhancing market reach

Investment Thesis

Syncom Formulations (India) Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This combination positions the company for sustained growth and profitability in the evolving pharmaceutical landscape.

  • Strong promoter group with a proven track record enhances investor confidence.
  • Digital services expansion aligns with industry trends, offering substantial growth potential.
  • Valuation metrics indicate Syncom is undervalued compared to its peers, presenting a buying opportunity.
  • Robust financials and consistent performance signal reliability and resilience.
  • Strategic initiatives in R&D and market expansion support long-term growth prospects.

Opportunity vs Risk

Opportunities
  • Growing demand for generic drugs
  • Expansion into international markets
  • Strong product pipeline
  • Strategic partnerships with healthcare firms
Risks ⚠️
  • Regulatory challenges in drug approvals
  • High competition in pharmaceuticals
  • Dependency on key suppliers
  • Fluctuating raw material costs

Peer Perspective

Syncom Formulations trades at a discount to peers like Aarti Drugs and Granules India, primarily due to margin volatility. A sustained improvement in margins could trigger a rerating, aligning it closer to its competitors.

Future Outlook

Syncom Formulations (India) Ltd is poised for growth, driven by expanding market opportunities. However, successful execution and stringent cost control will be crucial to fully realize its potential in the competitive pharmaceutical landscape.

AI FAQs for Retail Users

  • Q: What does Syncom Formulations (India) Ltd do?
    A: Syncom Formulations specializes in manufacturing and marketing pharmaceutical formulations and products.
  • Q: Is Syncom Formulations listed on Indian stock exchanges?
    A: Yes, Syncom Formulations is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
  • Q: What factors influence Syncom Formulations' stock price?
    A: Stock price can be influenced by company performance, market trends, and overall economic conditions.
  • Q: How can I invest in Syncom Formulations?
    A: You can invest through a brokerage account that allows trading on Indian stock exchanges.
  • Q: Are there any risks associated with investing in Syncom Formulations?
    A: As with any investment, risks include market volatility and company-specific challenges.
📊 Stock Investment Checklist (100 Points)
Syncom Formulations (India) Ltd • Updated: 2025-09-17 17:16:14
  • 8
    Business
    High
    Pharmaceutical sector shows growth potential, but competition is high.
  • 10
    Growth
    High
    Inconsistent revenue growth over the past few years.
  • 10
    Profitability
    High
    Moderate ROE and ROCE, but cash flow is not stable.
  • 9
    Valuation
    High
    P/E ratio is higher than industry average, indicating overvaluation.
  • 7
    Balance
    High
    Manageable debt levels but low liquidity ratios.
  • 6
    Governance
    Good
    Promoter holding is decent, but some pledging exists.
  • 5
    Drivers
    Good
    Limited growth drivers identified; execution risks are significant.
  • 1
    Technicals
    Low
    Weak market sentiment and poor price action.
Final Score & Verdict
Score 48 / 100 • Risky
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.

AI Confidence Score

Instead of just “overall score,” broken into categories:

  • Business Strength: 60/100
  • Growth Potential: 65/100
  • Profitability: 55/100
  • Governance: 50/100
  • Market Confidence: 60/100


More Like This

Latest News

More ↗

News items are fetched from Google News RSS; links go to external publishers.